BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD • US0906831039

2.12 USD
-0.03 (-1.4%)
At close: Feb 27, 2026
2.12 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, BTMD scores 5 out of 10 in our fundamental rating. BTMD was compared to 192 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BTMD was profitable.
  • In the past year BTMD had a positive cash flow from operations.
  • Of the past 5 years BTMD 4 years were profitable.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • BTMD has a Return On Assets of 25.87%. This is amongst the best in the industry. BTMD outperforms 98.44% of its industry peers.
  • BTMD has a Return On Invested Capital of 45.22%. This is amongst the best in the industry. BTMD outperforms 99.48% of its industry peers.
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROIC 45.22%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

  • BTMD has a better Profit Margin (14.72%) than 86.98% of its industry peers.
  • BTMD's Profit Margin has declined in the last couple of years.
  • BTMD has a better Operating Margin (16.09%) than 86.46% of its industry peers.
  • In the last couple of years the Operating Margin of BTMD has declined.
  • The Gross Margin of BTMD (72.23%) is better than 79.69% of its industry peers.
  • BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, BTMD has less shares outstanding
  • Compared to 1 year ago, BTMD has a worse debt to assets ratio.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.22 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BTMD (2.22) is better than 63.54% of its industry peers.
  • The Debt to FCF ratio of BTMD is 4.18, which is a neutral value as it means it would take BTMD, 4.18 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.18, BTMD belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Altman-Z 2.22
ROIC/WACC4.89
WACC9.25%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.01, BTMD is not doing good in the industry: 83.85% of the companies in the same industry are doing better.
  • BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 84.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.72
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 190.00% over the past year.
  • Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
  • The Revenue for BTMD has decreased by -18.44% in the past year. This is quite bad
  • Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%

3.2 Future

  • BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
  • BTMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 2.44, the valuation of BTMD can be described as very cheap.
  • BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.44% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BTMD to the average of the S&P500 Index (27.10), we can say BTMD is valued rather cheaply.
  • The Price/Forward Earnings ratio is 8.31, which indicates a very decent valuation of BTMD.
  • BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 91.67% of the companies in the same industry.
  • BTMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.44
Fwd PE 8.31
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 96.35% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaply inside the industry as 98.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.81
EV/EBITDA 6.05
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BTMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y7.66%
EPS Next 3Y9.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOTE CORP -A

NASDAQ:BTMD (2/27/2026, 8:00:02 PM)

After market: 2.12 0 (0%)

2.12

-0.03 (-1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-11
Inst Owners63.14%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap96.80M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target4.94 (133.02%)
Short Float %5.79%
Short Ratio10.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0.87%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE 2.44
Fwd PE 8.31
P/S 0.49
P/FCF 2.81
P/OCF 2.42
P/B N/A
P/tB N/A
EV/EBITDA 6.05
EPS(TTM)0.87
EY41.04%
EPS(NY)0.26
Fwd EY12.03%
FCF(TTM)0.75
FCFY35.55%
OCF(TTM)0.88
OCFY41.32%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROCE 57.24%
ROIC 45.22%
ROICexc 92.24%
ROICexgc 190.38%
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
FCFM 17.59%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Debt/EBITDA 3.02
Cap/Depr 144.67%
Cap/Sales 2.85%
Interest Coverage 3.81
Cash Conversion 113.15%
Profit Quality 119.51%
Current Ratio 1.01
Quick Ratio 0.72
Altman-Z 2.22
F-Score7
WACC9.25%
ROIC/WACC4.89
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%

BIOTE CORP -A / BTMD FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 5 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.